The role of B cells in the pathogenesis of systemic sclerosis
dc.creator | Sakkas L.I., Bogdanos D.P. | en |
dc.date.accessioned | 2023-01-31T09:53:16Z | |
dc.date.available | 2023-01-31T09:53:16Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 15651088 | |
dc.identifier.uri | http://hdl.handle.net/11615/78722 | |
dc.description.abstract | Systemic sclerosis (SSc) is characterized by extensive collagen deposition, microvasculopathy and autoantibodies. All three features can be promoted by activation of T cells and B cells. T cells are of Th2 type producing profibrotic cytokines IL-4 and IL-13 and inducing dendritic cell maturation that promotes Th2 response. B cells are overactivated and promote fibrosis by autoantibodies that activate fibroblasts or inhibit the degradation of extracellular matrix. They also promote fibrosis by cell-cell contact with fibroblasts or dendritic cells. B cells, through autoantibodies, may promote vasoconstriction and obliterative vasculopathy. They may also sustain activation of T cells by functioning as antigen-presenting cells. An immunoregulatory subset of B cells, namely IL-10-producing Bregs, is decreased in SSc. Finally, B cells have a critical role in animal models of SSc. All this evidence suggests an important role for B cells in the pathogenesis of SSc and makes B cells a potential target for therapeutic intervention in this disease. © 2016, Israel Medical Association. All rights reserved. | en |
dc.language.iso | en | en |
dc.source | Israel Medical Association Journal | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84989844980&partnerID=40&md5=97d7bf31cb9fa3603f472210d2fb1bc7 | |
dc.subject | angiotensin I | en |
dc.subject | autoantibody | en |
dc.subject | bleomycin | en |
dc.subject | CD19 antigen | en |
dc.subject | CD22 antigen | en |
dc.subject | fibrillin | en |
dc.subject | interleukin 10 | en |
dc.subject | interleukin 13 | en |
dc.subject | interleukin 4 | en |
dc.subject | interleukin 6 | en |
dc.subject | matrix metalloproteinase | en |
dc.subject | platelet derived growth factor receptor | en |
dc.subject | rituximab | en |
dc.subject | transforming growth factor beta | en |
dc.subject | autoantibody | en |
dc.subject | collagen | en |
dc.subject | cytokine | en |
dc.subject | interleukin 10 | en |
dc.subject | antigen presenting cell | en |
dc.subject | Article | en |
dc.subject | B lymphocyte | en |
dc.subject | B lymphocyte activation | en |
dc.subject | cell contact | en |
dc.subject | dendritic cell | en |
dc.subject | fibroblast | en |
dc.subject | human | en |
dc.subject | interstitial lung disease | en |
dc.subject | lung fibrosis | en |
dc.subject | nonhuman | en |
dc.subject | regulatory T lymphocyte | en |
dc.subject | skin fibrosis | en |
dc.subject | systemic sclerosis | en |
dc.subject | T lymphocyte activation | en |
dc.subject | Th2 cell | en |
dc.subject | vasoconstriction | en |
dc.subject | animal | en |
dc.subject | B lymphocyte | en |
dc.subject | disease model | en |
dc.subject | fibrosis | en |
dc.subject | immunology | en |
dc.subject | metabolism | en |
dc.subject | pathophysiology | en |
dc.subject | systemic sclerosis | en |
dc.subject | T lymphocyte | en |
dc.subject | Animals | en |
dc.subject | Autoantibodies | en |
dc.subject | B-Lymphocytes | en |
dc.subject | Collagen | en |
dc.subject | Cytokines | en |
dc.subject | Dendritic Cells | en |
dc.subject | Disease Models, Animal | en |
dc.subject | Fibroblasts | en |
dc.subject | Fibrosis | en |
dc.subject | Humans | en |
dc.subject | Interleukin-10 | en |
dc.subject | Scleroderma, Systemic | en |
dc.subject | T-Lymphocytes | en |
dc.subject | Israel Medical Association | en |
dc.title | The role of B cells in the pathogenesis of systemic sclerosis | en |
dc.type | journalArticle | en |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |